|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |